PREDICTORS FOR OFF-THERAPY HBEAG SERO-REVERSION HEPATITIS AND HBEAG-NEGATIVE HEPATITIS IN HBEAG-POSITIVE PATIENTS DISCONTINUE NUC THERAPY ARE DIFFERENT

被引：0
|
作者：
Peng, Chien-Wei [1 ,2 ]
Jeng, Wen-Juei [1 ,2 ]
Chien, Rong-Nan [1 ,2 ,3 ]
Liaw, Yun-Fan [2 ,4 ]
机构：
[1] Chang Gung Mem Hosp, Linkou Med Ctr, Dept Gastroenterol & Hepatol, Taoyuan, Taiwan
[2] Chang Gung Univ, Coll Med, Taoyuan, Taiwan
[3] Chang Gung Mem Hosp, Linkou Branch, Liver Res Unit, Taoyuan, Taiwan
[4] Chang Gung Mem Hosp, Liver Res Unit, Linkou, Taiwan
来源：
HEPATOLOGY | 2021年 / 74卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
797
引用
收藏
页码：489A / 490A
页数：2
相关论文
共 50 条
  • [1] What Should Be the Endpoints of Oral Therapy in HBeAg-positive Versus HBeAg-negative Patients with Chronic Hepatitis B
    Stephanos J. Hadziyannis
    Dimitrios Vassilopoulos
    Current Hepatitis Reports, 2012, 11 (2) : 65 - 69
  • [2] DISTINCT DIFFERENT RELAPSE PATTERNS BUT SIMILAR HBEAG SERO-REVERSION RATE AFTER CESSATION OF ENTECAVIR AND TENOFOVIR IN HBEAG-POSITIVE CHRONIC HEPATITIS B PATIENTS
    Peng, Chien-Wei
    Jeng, Wen-Juei
    Liu, Yen-Chun
    Chien, Rong-Nan
    Liaw, Yun-Fan
    HEPATOLOGY, 2021, 74 : 476A - 477A
  • [3] PREDICTORS OF DEVELOPMENT OF HBEAG-NEGATIVE CHRONIC HEPATITIS B FOLLOWING PEGINTERFERON ALFA-2A THERAPY IN HBEAG-POSITIVE CHRONIC HEPATITIS B
    Peng, Cheng-Yuan
    Shih, Chao-Jen
    Lo, Pei-Shuan
    Huang, Chia-Lin
    Lai, Hsueh-Chou
    Su, Wen-Pang
    Chuang, Po-Heng
    Kao, Jung-Ta
    HEPATOLOGY, 2011, 54 : 1027A - 1028A
  • [4] HBsAg Kinetics in Retreatment Decision for Off-Therapy Hepatitis B Flare in HBeAg-Negative Patients
    Liaw, Yun-Fan
    Jeng, Wen-Juei
    Chang, Ming-Ling
    GASTROENTEROLOGY, 2018, 154 (08) : 2280 - 2281
  • [5] The main reasons for finite Nuc therapy in HBeAg-negative chronic hepatitis B patients
    Peng, Chien-Wei
    Jeng, Wen-Juei
    HEPATOLOGY INTERNATIONAL, 2021, 15 (02) : 527 - 528
  • [6] The main reasons for finite Nuc therapy in HBeAg-negative chronic hepatitis B patients
    Chien-Wei Peng
    Wen-Juei Jeng
    Hepatology International, 2021, 15 : 527 - 528
  • [7] Compared the effect of lamivudin in the hepatitis B patients between HBeAg-negative group and HBeAg-positive group
    Jiang, Jianning
    Su, Minghua
    Zhou, Yuanping
    Wu, Jizhou
    Liu, Zhihong
    Wei, Ying Hua
    Huang, Liyi
    Yu, Yanhong
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A118 - A118
  • [8] Kinetics of serum HBsAg and intrahepatic cccDNA during pegylated interferon therapy in patients with HBeAg-positive and HBeAg-negative chronic hepatitis B
    Chuaypen, Natthaya
    Sriprapun, Methee
    Praianantathavorn, Kesmanee
    Payungporn, Sunchai
    Wisedopas, Naruemon
    Poovorawan, Yong
    Tangkijvanich, Pisit
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 31 : 373 - 373
  • [9] Kinetics of serum HBsAg and intrahepatic cccDNA during pegylated interferon therapy in patients with HBeAg-positive and HBeAg-negative chronic hepatitis B
    Chuaypen, Natthaya
    Sriprapun, Methee
    Praianantathavorn, Kesmanee
    Payungporn, Sunchai
    Wisedopas, Naruemon
    Poovorawan, Yong
    Tangkijvanich, Pisit
    JOURNAL OF MEDICAL VIROLOGY, 2017, 89 (01) : 130 - 138
  • [10] DIFFERENCE OF SERUM CYTOKINES EXPRESSION BETWEEN HBeAg-POSITIVE AND HBeAg-NEGATIVE CHRONIC HEPATITIS B
    He, D.
    Guo, S.
    Li, M.
    Zeng, X.
    Huang, H.
    Tan, Z.
    Wang, Y.
    JOURNAL OF HEPATOLOGY, 2015, 62 : S535 - S535
12345